Development of peptidomimetic boronates as proteasome inhibitors

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Oncology

Background:

• Proteasome inhibition is a key strategy for treating hematologic malignancies.
• The proteasome is a multicatalytic complex with chymotrypsin-like (β5), trypsin-like (β2), and caspase-like (β1) activity.
• Inhibition of the β5 subunit is crucial for developing effective anticancer agents.

Purpose of the Study:

• To synthesize and biologically evaluate novel conformationally constrained pseudopeptide boronates.
• To assess the inhibitory profile and selectivity of these compounds against proteasome activity.
• To provide insights for optimizing future proteasome inhibitor drug discovery.

Main Methods:

• Synthesis of a series of pseudopeptide boronate compounds.
• In vitro evaluation of proteasome inhibition, determining Ki values.
• Selectivity testing against bovine pancreatic α-chymotrypsin.
• Molecular docking experiments using a yeast 20S proteasome model.

Main Results:

• Synthesized compounds demonstrated promising inhibition of proteasome activity, primarily targeting the chymotrypsin-like (β5) subunit.
• Inhibitory constants (Ki) were in the submicromolar/micromolar range.
• Compounds exhibited good selectivity, with no significant inhibition of bovine pancreatic α-chymotrypsin.
• Docking studies provided structural insights into the binding interactions.

Conclusions:

• The novel pseudopeptide boronates are potent and selective inhibitors of the chymotrypsin-like proteasome activity.
• These findings support their potential as therapeutic agents for hematologic malignancies.
• The study offers valuable information for the rational design of next-generation proteasome inhibitors.